This paper analyzes the changing R&D process at Japanese pharmaceutical companies, based on a questionnaire survey as well as structured interviews at large Japanese pharmaceutical companies.
Introduction
The Japanese innovation system has been characterized as an "in-house development model dominated by large firms" (Motohashi, 2001 ). This applies as well to pharmaceutical development. Kneller (2003) analyzes the autarkic drug discovery process in Japanese companies compared to that for non-Japanese companies by performed structured interview surveys. He shows that the rate of in-licensed ["in-license"] lead compounds for the drug discovery process in Japanese companies is systematically lower than that for non-Japanese companies. In addition, he identifies both supply and demand factors for inactive R&D collaboration, such as the lack of strong domestic biotech companies and the internal orientation of R&D at large pharmaceutical companies.
However, on the other hand, studies appear to indicate that large Japanese firms have begun an active engagement in R&D collaboration activities, particularly in the pharmaceutical sector (RIETI, 2004) .
Progress in molecular biology and in biotechnology, such as new drug development techniques based on genomic information, has led to dramatic changes in the pharmaceutical R&D process. This trend has increasingly underscored the importance of basic research in R&D for new drugs, forcing pharmaceutical companies to collaborate with universities and biotech firms. While the response of Japanese firms has been relatively slow, such trends cannot be ignored in a world of global competition.
The changing market conditions for pharmaceuticals is another major factor driving the growth in external R&D collaborations. Various regulations under the Pharmaceutical Affairs Law are currently being revised. The fundamental idea behind this regulatory reform is to introduce market based competition and international harmonization. Intense international competition increased the incentive for developing "innovative drugs" rather than "me too drugs" representing minor improvements on existing drugs. In turn, this has led to changes in the R&D scope of pharmaceutical companies, encouraging collaboration in start-up companies in biotechnology, so-called "biotech firms". In addition, innovation policies also affect company R&D. Biotechnology is a crucial technological area, one into which the government has poured massive funding for public R&D. In addition, recent policy initiatives to facilitate university industry partnerships as well as pro-patent IPR system reform also represent important factors in pharmaceutical R&D. This paper analyzes the changing R&D process within Japanese pharmaceutical companies, based on a questionnaire survey and a structured interview survey of large Japanese pharmaceutical companies.
These surveys examine recent trends in external R&D collaboration and identifies underlying factors.
The factors are classified into three broad categories; (1) technological opportunity factors such as the effect of biotechnology advances on new drug development; (2) market condition factors such as regulatory reform affecting pharmaceuticals; and (3) innovation policy factors that promote university/industry joint ventures and IPR policy reforms. The content of R&D collaboration projects differ with respect to counterparts, as well as by the stage of pharmaceutical R&D process. For example, technology opportunity factors, such as increasing use of genomic data, are more important in the process upstream of drug discovery and in collaborations with universities and public research organizations. In contrast, intense market competition encourages accelerated drug development. In this context, a firm may increase use of CROs (contract research organizations) in the clinical test phase. Our survey instruments are designed to clarify such complexities characteristic of the external R&D collaborations of pharmaceutical companies. This paper is organized as follows. The following section provides an overview of R&D collaboration activities involving pharmaceutical companies. The Survey of Research and Development by Statistical Bureau gives a broad picture of recent trends at the industry level. In this section, three categories of factors underlying increasing R&D collaboration are also discussed in detail. This is followed by a presentation of the results of the questionnaire and interview surveys and a discussion of these results. The factors underlying pharmaceutical R&D partnerships do not exert their effects in isolation; such factors interact. The concept of national innovation system is used to provide a comprehensive overview of pharmaceutical innovation. Finally, the paper concludes with a summary of our findings and some policy implications. Total R&D expenses for the pharmaceutical industry are 887.5 billion yen, of which 15.9% is paid to external entities. On the other hand, the share of contracted in R&D within the total R&D budget is a mere 1.5%. The share of outsourced R&D in the pharmaceutical industry exceeds the average for all industries, while that of contracted-in R&D is lower. That is, Japanese pharmaceutical companies engage in R&D collaboration primarily by buying certain technologies from external entities. Figure 2 shows trends in in-house and outsourced R&D, while Figure 3 shows the share of R&D outsourced by type of outsourcing counterpart. As Figure 2 makes clear, the growth rate of overall R&D expenses of the pharmaceutical industry has declined from the early 90s, while the ratio of outsourced R&D expenses has consistently increased. As a result, the ratio of R&D outsourced to in-house R&D is growing. Figure 3 shows that the share of R&D paid out to foreign organizations and firms is increasing, reaching approximately 40% around 2000. Hirai (2002) performed a detailed analysis of external collaborations in R&D, using a database based on US financial reports to the SEC. In this analysis, he thoroughly analyzed these partnerships from various viewpoints, including the identity of contracting partners, the subject of the projects, and the stage of R&D process. According to his results, the most common type of alliance partner for Japanese pharmaceutical companies is biotech companies, most of which are located in the US. Hirai (2002) also discussed changes in the number of alliances for each R&D stage. The pharmaceutical R&D process starts with a target compound for development, followed by screening of the compound, crucial to find efficient ways to discover lead compounds that offer promising as new drugs. Figure 4 illustrates the ways in which the new drug development process has changed with progress in biotechnology.
( Figure 4) Penicillin, the first pioneering drug at the dawn of modern pharmaceuticals, was originally discovered in a species of mold that exhibits antibiotic activity. In similar ways, the traditional R&D procedure for new drug development targeted biologically active compounds found in natural substances. The R&D program in the pharmaceutical industry comprises a process for discovering target compounds for the development of new drugs and a series of screening processes for examining the benefits and adverse effects of these new compounds -for example, through animal studies.
2 After World War II, pharmaceutical companies, primarily in the US, made remarkable progress, presumably due to the lack of any drugs immediately after the war. At this time, penicillin was one of few widely effective drugs available, leaving the field of research and development in new drugs open to competition. Random screening proved to be a relatively effective approach to R&D for pharmaceutical companies in those days, and in this process, new bioactive compounds present in natural substances were screened and examined one after another for their effectiveness as new drugs (Cockburn et al., 1999 Genetic recombinant technology resolved these problems.
Biopharmaceuticals produced in a similar manner are currently plentiful, including human growth hormone, erythropoietin, G-CSF, and interferon, all of which are derived from proteins present in the human body and cultivated on a large scale by biotechnology. Figure 4 refers to these first-generation biopharmaceuticals. The R&D process for the development of these drugs is a radical departure from the traditional process through which target compounds for new drugs were discovered and screened.
The effective development of these peptide/protein pharmaceuticals required new technologies qualitatively different from those for conventional new drug research and development, including genetic recombination, insertion of vectors into plasmids, protein production (e.g., by cultivation of host cells), and glycotechnology (Hayakawa and Ishii, 2002) . In the fields that demand these new technologies, the pharmaceutical companies lacked adequate in-house human resources, making it more effective to establish external partnerships. In addition, the expansion of these new technical fields in the area of pharmaceutical research and development led to the participation of several new players from other business sectors, such as Kirin Brewery Co., Ltd., Suntory Limited, and Meiji Seika Kaisha, Ltd.
Another important trend in biotechnological drug development is the implementation of more efficient methods for the discovery and screening of new drugs targeting genes based on human genetic information. The R&D process for the development of such drugs, called second-generation biopharmaceuticals in Figure 4 , is similar to the process of traditional pharmaceutical R&D. However, it differs in that pharmaceutical R&D is based on scientific reasoning employing human genetic information rather than trial-and-error. For example, Herceptin, an anticancer drug prescribed for metastatic breast cancer patients, was developed by identifying HER2 receptor genes overexpressed in patients and by screening potential ligands that block the receptor. Although Herceptin is an antibody drug developed by taking advantage of immunological reactions that take place in organisms, other drugs targeting specific molecules are currently under development. Such drugs are effective against low-molecular weight compounds that act specifically on particular proteins to induce carcinogenesis (Nikkei Science, 2001 ).
While the R&D program for second-generation biopharmaceuticals is quite similar to that for conventional pharmaceuticals, it differs in the abundant scientific knowledge applied to early screening processes. Second-generation drugs are developed through an understanding of physiological mechanisms at the molecular level. Such development capitalizes on techniques for functional analysis of genes and functional/structural analyses of proteins, and also makes use of bioinformatics (e.g., for screening of pathogenic genes). Such development is known as "genomic drug development" or "drug development in the post-genomic era." In the key biotechnologies needed for pharmaceutical development, including bioinformatics and techniques for functional genetic analysis, the US is the front-runner, based on the number and quality of patents filed. This state of affairs has compelled Japanese pharmaceutical companies to collaborate with universities and biotech companies in the US. about 85% of which was accounted for by prescription drugs, which are more R&D intensive than over the counter drugs. The following subsection of the paper discusses market condition factor underlying R&D collaboration, focusing on prescription drugs.
The domestic market for prescription drugs expanded steadily until about 1990, reaching a stable plateau thereafter at approximately 7 trillion yen. In contrast, the worldwide market for prescription drugs has continued to grow, in part due to the booming US market. (Figure 5 ) Thus, the share of the world market represented by the Japanese market has declined. In addition, the ratio of imported products into the domestic market has grown. More recently, the share of foreign-affiliated pharmaceutical companies has also expanded, increasing competition in the domestic market ( Figure   6 ). Because the worldwide market, primarily the US market, continues to grow in contrast to sluggish growth in the domestic market, Japanese major pharmaceutical companies in their R&D process are targeting globally competitive drugs. Law. The price of each prescription drug is specified by the drug price standard (DPS) stipulated under the Health Insurance Law, and the price is set by comparison to the price of similar drugs, with adjustments for originality, usefulness, and marketability of the drug. This listed drug price has gradually declined since the mid '80s due to DPS revisions. Especially from 1992, when a new method was established for determining the price of a drug, based on the weighted average of the drug in the market within a fairly broad range, drug prices have declined every 1 or 2 years. 4 This reflects the government goal of suppressing prescription drug expenses under the broader framework of maintaining low heath care costs.
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In addition to declining domestic market for prescription drugs, an increase in the number of imported products and the entry of foreign companies has increased competition in the domestic market.
Despite a gradual decline in its share in global market, the Japanese market still accounts for better than 15% of the world market, a proportion that remains attractive for foreign companies. foreign companies from entering the Japanese market. At the same time, the amendment also forced Japanese pharmaceutical companies to strengthen their capabilities domestically in a manner that helped prepare them to conduct similar clinical tests abroad for their entry into overseas markets.
The intensified competition and globalization of the domestic market have led to various effects on the pharmaceutical R&D process. First, Japanese pharmaceutical companies engaged in R&D to enter the global market are shifting the emphasis of drug development programs from improving conventional products to developing completely innovative products. A scheme for "innovation supplement" to a drug price in the determination of the drug price standard (DPS) was introduced as an incentive for innovative drug development in 1991, and the scale of the price supplements was further increased in 2000 and 2002. 7 The globalization of the domestic market has also led to increasing numbers of partnerships and joint ventures involving Japanese companies and foreign pharmaceutical companies, hospitals, and clinical research organizations (CRO). The major motivation for this international alliance is strengthening organizations in the U.S., and reimbursed, but at low levels in France. market position in each market mutually. In addition, using CRO in international market is essential for Japanese companies which do not have enough experience on clinical tests outside of Japan.
(4) Innovation policy factor behind R&D collaboration
The R&D process for new drugs has changed significantly alongside progress in biotechnology. A process of discovery and screening of drugs by trial and error has gradually been replaced by one based on scientific knowledge, much of which is discovered in universities and public research organizations. Cockburn and Henderson (2001) have shown that basic research conducted in public research organizations in the US increased productivity in many aspects of pharmaceutical R&D, including human resources training and the supply of advanced research tools. Biotechnology advances are increasingly changing the pharmaceutical industry into a science-based industry.
Accordingly, the role of public research organizations and public policy are becoming more important in promoting pharmaceutical innovations (Kuwashima and Odagiri, 2003) .
In this context, the recent policy of promoting university-industry partnerships facilitates We have responses from 14 firms. In addition, we conducted structured interviews of the 10 largest companies, including 2 companies that did not respond to the questionnaire survey. Although this sample size is small, the firms in our data perform more than 50% of the total R&D of the 8 To ensure exclusive rights to a technology, a variety of methods are available other than patent right; for example, by making production processes and product designs more complicated and by concealment of technological information. However, the importance of the patent system is greater in the pharmaceutical industry than in other industries (Cohen et. al, 2002; Goto and Nagata, 1996) . 9 Member companies of the R&D committee at the Japan Pharmaceutical Manufacturers Association (JPMA) pharmaceutical industry. Thus, the results from this survey may represent industry trends in R&D. -Collaborations with universities were formerly implemented in such a way that left ownership of research results ambiguous. However, these partnerships are now more conducted on a formal contract basis, presumably due to the establishment of guidelines for joint research and of TLOs in universities.
-Pharmaceutical companies rarely accept patent licenses from universities as it is. Instead, they prefer to take research concepts generated in universities and further develop them in joint research.
-Recent initiatives at universities for closer ties with industry, such as the establishment of TLOs, will undoubtedly lead to more collaboration. However, Japanese universities lag significantly behind US universities with respect to dealing with industry representatives for commercial reasons (Joint research projects with and licensing from overseas biotech companies) -Japanese pharmaceutical companies collaborate with overseas biotech companies in a restricted and focused area. In many cases, partnerships are conducted under a set of license agreements for a patent granted to the biotech company and a co-R&D contract for patent development.
-Major joint efforts include (1) use of databases on gene function and (2) Furthermore, despite great enthusiasm for use of genetic information to speed effective drug discovery, it is not generally acknowledged to have led directly to any improvements in speed and efficiency.
While companies are keenly aware of and are in fact currently tackling issues related to improved R&D efficiency, they do not believe that the new genomic methods have led to improved efficiency thus far. This may be one reason they use R&D collaboration extensively on such front end R&D projects.
Finally, the results of the questionnaire survey on factors underlying the increasing importance of external collaborations are presented in Figure 9 . Technology opportunity factors, such as "expansion of research fields, including discovery of genomic drugs" and "importance of scientific knowledge in product development" are important factors for strengthening partnerships with universities and public research organizations. Additionally, market condition factors such as "changes in the regulatory environment such as suppression of the drug price standard (DPS)" and "intensified competition due to the penetration of foreign-affiliated companies into the domestic market" affect partnerships with other pharmaceutical companies. Innovation policy factors for promoting biotechnology significantly influence partnerships with universities and public research organizations, while measures granting patents for gene fragments and research tools affect partnerships with biotech companies.
( Figure 9 )
Interview surveys reveal similar perceptions among pharmaceutical companies as those from questionnaire survey. One comment worth making here is that we had insufficient time to evaluate the impact of university industry linkage policy. Patents in new fields such as gene fragment patents have particularly significant effects on partnerships. Finally, collaborations with clinical institutions are perceived as increasingly important, and information from medical treatment sites may be used to further the drug development process.
Discussions
Interview surveys indicate the interaction of various kinds of factors explaining increasing R&D collaboration activities by Japanese pharmaceutical companies. We need to understand the whole picture as a system. In this context, the concept of a national innovation system may be used as a framework of analysis. The concept of a national innovation system (NIS) incorporates interactions of innovation activities among firms, universities, and other research organizations, as well as economic institutions governing such activities, such as corporate laws, competition laws, and intellectual property laws. Needless to say, R&D activity in each company is a major source of innovation.
However, it is also important to understand the company's innovations in broader terms, including technological spillover from universities and other research organizations, and framework conditions for innovative activities such as appropriate product market conditions, labor market mobility, and IPR systems.
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The Japanese innovation system is characterized by "in-house development system dominated by large companies," differing markedly from network-type innovation systems found in the US. (Motohashi, 2001 ). Background factors shaping this Japanese system include low mobility of researchers in companies and universities, the short supply of venture capital for start-up companies, the tendency of universities to focus on basic research, and the inward orientation of corporate research activities. In the case of the pharmaceutical industry, it is also important to note that drug prices are still heavily regulated by the government. While this gradually changed, current incentives for developing innovative drug are still insufficient if we compare it with US system.
10 See Nelson (1993) for a summary of an international comparison of national innovation systems. In addition, see OECD (1999) for a summary of a recent survey conducted by OECD on national innovation systems.
Amid changes in R&D processes for new drugs with progress in biotechnology, various innovations in the development of new pharmaceuticals have occurred, mainly in biotech companies in the US. In contrast, Japan was left behind, presumably because a system dominated by large companies hinders innovation by start-up companies. This may also be due to the generally low level of basic research in fields such as molecular biology in Japanese universities (Cockburn and Henderson, 2001) . In this sense, it should be noted that entries into biopharmaceutical development often come from diversification of existing companies, such as Japan Tobacco Inc. and Kirin Brewery Co, Ltd. This may serve as an effective model for a Japanese system that lacks the dynamics of corporate entry and exit.
What specific systemic problems do we face, from the viewpoint of the innovation system of a pharmaceutical industry? Figure 10 summarizes the interactions of relevant factors explaining the pharmaceutical innovation system of Japan revealed in the previous section. The pharmaceutical R&D process has changed dramatically with progress in biotechnology. Japanese pharmaceutical companies, recognizing expanding technological opportunities which they are not equipped to handle with their own human resources and technologies, have strengthened R&D collaborations with external organizations. Our survey of pharmaceutical companies indicates that companies are strengthening collaborations, particularly with domestic universities and public research organizations and with overseas biotech companies. However, detailed examination of the collaboration reveals that the purpose of the collaborations with domestic universities and public research organizations is merely to obtain general knowledge, while licenses and joint research of more focused topics are conducted with overseas biotech companies. In addition, Figure 3 shows that the share of R&D outsourced to the domestic public sector, including universities and public research institutes, is very small, R&D collaboration with Japanese universities is small and has relatively insignificant impact on the corporate R&D process.
( Figure 10 ) Japanese pharmaceutical companies are attempting to keep pace with changes in pharmaceutical R&D processes associated with progress in biotechnology by tapping the global innovation network, particularly in the US. However, this move is believed to lag significantly behind those of pharmaceutical companies in the US, England, and Switzerland (Cockburn et al., 1999) . 11 Perhaps geographic distance affects technology spillover (Jaffe et al., 1993) . External R&D collaboration demands information on the partner and an evaluation of the content and level of the development of its technologies. Companies must be able to assess potential partners and to obtain the comprehensive information needed to make such judgments. Of course, geographic distance is a critical factor in such determinations. Furthermore, the spillover of technology from one country to another faces obstacles involving linguistic barriers. Although Japanese drug makers have already established many research bases abroad, the scale of such operations is far below that of mega-pharma outside Japan.
In this context, it is important to analyze the reasons that collaborations between pharmaceutical companies and Japanese universities or public research organizations remain inadequate, and why biotech companies spun off from universities are less common in Japan than in the US. Currently, the Japanese government is increasing public funding for biotechnology projects. In order for such governmental measures to produce innovations in the Japanese pharmaceutical industry, efficient university-industry partnerships are essential.
According to Zucker et al. (1998) , bio-company-university clusters in the US generally involve a star scientist at a university, who conveys, through research cooperation in university-industry partnerships, knowledge and technology to companies located nearby. In this way, scientific knowledge capable of improving the efficiency of pharmaceutical innovations moves with scientist turnovers. In contrast, the labor market of scientists in Japan is rigid, perhaps impeding the flow of scientists and knowledge.
Following the university reform of 2004, incentive systems for university to collaborate with firms have been strengthened. In addition, professors at national universities can now work with private companies in more flexible ways. However, network based innovation system with active university industry collaborations cannot be achieved without greater mobility of researchers across sectors. In this regard, inflexible labor market institutions in Japan remain a bottleneck to systemic reform.
Conclusions
Pharmaceutical R&D processes have changed significantly with progress in biotechnology.
Conventional methods of trial and error in discovery and drug screening are gradually being displaced by new more deductive methods of discovery and screening based on scientific knowledge. Japanese pharmaceutical companies are intensifying R&D collaborative efforts with external organizations to meet the changes brought about by these new technologies. In addition, in intensified competition resulting from internationalization of the Japanese pharmaceutical market, Japanese pharmaceutical companies are shifting their emphasis to the development of more innovative drugs that can compete in the global market. These demand pressures are also driving pharmaceutical companies to acquire state-of-the-art biotechnologies for their R&D.
This paper analyzed the causes and consequences of the recent upward trend in external R&D collaborations of Japanese pharmaceutical companies. Three broad factors behind this trend are identified: technology opportunity, market conditions, and innovation policies. All of these factors are in some sense related to such trends. However, more importantly, these factors are interrelated, forming a complex system. Based on the framework of a national innovation system, we found that Japanese pharmaceutical companies are trying to link to a foreign innovation network, particularly in the US. Delays in partnerships with Japanese universities and other such institutions are presumably due to problems inherent in Japanese universities or in the general approach to university-industry partnerships. Judging from the number of biopharmaceutical patents granted, the technical capabilities of Japanese universities in the life sciences undoubtedly lags behind US universities (Japan Patent Office, 2001). However, we must examine more systemic issues to explain why research results in Japanese public sectors are not used effectively for pharmaceutical innovation.
In the US, university researchers frequently establish startup companies or engage in business biopharmaceuticals.
partnerships while visiting a corporate research laboratory. In contrast, in Japan, the number of venture companies spun off from universities remains limited. Pharmaceutical companies in university-industry partnerships generally send researchers to universities. The scientific knowledge accumulated at universities appears to be inadequately transferred and applied toward industrial innovation (Zucker and Darby, 2001 ). The national university reforms enacted in 2004 may lead to more active collaboration between industry and university. University spin-off companies are also encouraged by the government. However, fundamental changes cannot happen unless Japanese inflexible labor institutions change -an issue with more fundamental roots in the Japanese innovation system, the inactive external labor market hindering mobility of scientists across firms and organizations. The Japanese government has designated 'biotechnology' as a major technology field, investing significant amounts into public science. To stimulate innovation based on such publicly funded projects, policies addressing inflexibility of S&T labor market are critical. Figure 10: Biopharmaceutical innovation system in Japan
